Paradoxical effects of LS-2616 (Linomide) treatment in the type II collagen arthritis model in mice
- 1 June 1989
- journal article
- Published by Springer Nature in Inflammation Research
- Vol. 27 (3-4) , 319-321
- https://doi.org/10.1007/bf01972810
Abstract
The quinoline-3-carboxamide, Linomide, has been shown to possess potent immunomodulatory activity. We have evaluated the effect of Linomide in the type II collagen induced arthritis in mice. Treatment with Linomide (1.25–80 mg/kg/day) from the day of immunization strongly suppressed the arthritic response. On the other hand, initiation of treatment (20–80 mg/kg/day) at the onset of arthritis resulted in an increased severity of the arthritis. These potent and contradictory effects of Linomide, depending on treatment regime, indicates that central immuno-regulatory functions are affected and that this compound may be a useful tool for the understanding of autoimmune mechanisms.Keywords
This publication has 9 references indexed in Scilit:
- Mechanism of action of the new immunomodulator LS2616 on T cell responsesInternational Journal of Immunopharmacology, 1987
- EFFECTS OF LS-2616 ADMINISTRATION UPON THE AUTOIMMUNE-DISEASE OF (NZB X NZW) F1-HYBRID MICE1986
- Successful treatment of autoimmunity in mrl/1 mice with ls‐2616, a new immunomodulatorArthritis & Rheumatism, 1986
- Effects of the novel immunomodulator LS 2616 on the delayed-type hypersensitivity reaction to Bordetella pertussis in the ratImmunopharmacology, 1986
- Augmentation of mouse natural killer cell activity by LS 2616, a new immunomodulator.The Journal of Immunology, 1985
- ROLE OF T-LYMPHOCYTES IN COLLAGEN-II INDUCED ARTHRITIS IN RATS1983
- Collagen arthritis as a relevant model for rheumatoid arthritis. evidence pro and conArthritis & Rheumatism, 1982
- Immunisation against heterologous type II collagen induces arthritis in miceNature, 1980